Premium
Randomized dose‐ranging pilot trial of omega‐3 fatty acids for postpartum depression
Author(s) -
Freeman M. P.,
Hibbeln J. R.,
Wisner K. L.,
Brumbach B. H.,
Watchman M.,
Gelenberg A. J.
Publication year - 2006
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.2005.00660.x
Subject(s) - postpartum depression , hamilton rating scale for depression , edinburgh postnatal depression scale , randomized controlled trial , placebo , depression (economics) , medicine , hamilton depression scale , rating scale , fatty acid , gastroenterology , psychology , significant difference , pregnancy , major depressive disorder , chemistry , biology , hamd , biochemistry , developmental psychology , genetics , alternative medicine , macroeconomics , pathology , amygdala , economics
Objective: Postpartum depression (PPD) affects 10–15% of mothers. Omega‐3 fatty acids are an intriguing potential treatment for PPD. Method: The efficacy of omega‐3 fatty acids for PPD was assessed in an 8‐week dose‐ranging trial. Subjects were randomized to 0.5 g/day ( n = 6), 1.4 g/day ( n = 3), or 2.8 g/day ( n = 7). Results: Across groups, pretreatment Edinburgh Postnatal Depression Scale (EPDS) and Hamilton Rating Scale for Depression (HRSD) mean scores were 18.1 and 19.1 respectively; post‐treatment mean scores were 9.3 and 10.0. Percent decreases on the EPDS and HRSD were 51.5% and 48.8%, respectively; changes from baseline were significant within each group and when combining groups. Groups did not significantly differ in pre‐ or post‐test scores, or change in scores. The treatment was well tolerated. Conclusion: This study was limited by small sample size and lack of placebo group. However, these results support further study of omega‐3 fatty acids as a treatment for PPD.